K4 Elite
K4 Elite
A synthetic nonapeptide vasopressin analog selective for the V2 receptor, studied in renal water handling, aquaporin-2 trafficking and endothelial Weibel-Palade body exocytosis.
Desmopressin (1-desamino-8-D-arginine vasopressin, dDAVP) is a synthetic nonapeptide analog of arginine vasopressin. Two modifications define it: deamination at position 1 and substitution of D-arginine for L-arginine at position 8 [2].
Those changes shift the pharmacology sharply toward the V2 receptor and away from the V1a receptor that mediates vasoconstriction, while also extending the peptide half-life relative to native vasopressin. As a result it is used throughout the literature as the standard selective V2 agonist tool compound [1][5].
It is an approved medicine in multiple jurisdictions and appears in two largely separate research literatures: renal water handling and aquaporin biology on one side, and hemostasis and endothelial exocytosis on the other [2][6].
The V2 receptor is a class A GPCR expressed on renal collecting duct principal cells and on vascular endothelium. In collecting duct cells, receptor activation raises cAMP and activates protein kinase A, which phosphorylates aquaporin-2 at serine 256 and promotes trafficking of AQP2-bearing vesicles to the apical membrane; phosphorylation at S261, S264 and S269 is described as regulating endocytosis and membrane retention [4].
In endothelial cells the same V2-cAMP axis is reported to trigger exocytosis of Weibel-Palade bodies, releasing stored von Willebrand factor and tissue plasminogen activator, with parallel activation of endothelial nitric oxide synthase [1][5].
Kaufmann and Vischer reviewed cellular studies of dDAVP action and identified the endothelial V2 receptor-cAMP pathway as the proximate mechanism for Weibel-Palade body exocytosis, integrating cell-culture and ex vivo vascular data with measurements of von Willebrand factor, factor VIII and t-PA [1].
In rat studies of collecting duct physiology, investigators combined dDAVP infusion with urinary aquaporin-2 measurement and reported that AQP2 excretion follows a vasopressin-dependent apical pathway rather than basolateral shedding [4].
Working in cultured human endothelial cells, investigators showed that vasopressin-induced von Willebrand factor secretion required V2 receptor expression and was reproduced by cAMP-elevating agents, establishing receptor identity in that system [5].
Federici and colleagues summarized 30 years (1977-2007) of desmopressin use in von Willebrand disease cohorts, reporting marked response heterogeneity across VWD subtypes as the principal aggregated finding [3].
Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.